Protein / target

DNA-directed RNA polymerase subunit omega

rpoZP0A800Escherichia coli (strain K12)Swiss-Prot
UniProt: P0A800NCBI Gene: 948160
30
Clinical trials
1
Drugs targeting

Protein at a glance

Biological role

Bacterial-type RNA polymerase core enzyme binding

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function

Promotes RNA polymerase (RNAP) assembly. Latches the N- and C-terminal regions of the beta' subunit thereby facilitating its interaction with the beta and alpha subunits

Domains and Gene Ontology detail (19)

Gene Ontology

  • Ccytosol
  • Ccytosolic DNA-directed RNA polymerase complex
  • CRNA polymerase complex
  • Fbacterial-type RNA polymerase core enzyme binding
  • FDNA binding
  • FDNA-directed RNA polymerase activity
  • Pbacterial-type flagellum assembly
  • Pbacterial-type flagellum-dependent cell motility
  • Pcell motility
  • Pcellular response to cell envelope stress
  • PDNA-templated transcription initiation
  • Pintracellular iron ion homeostasis

91 aa · 10 kDa

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Transcriptional regulationGOImmune signallingGO
View supporting evidence

Transcriptional regulation

  • ·DNA-templated transcription initiation
  • ·regulation of DNA-templated transcription elongation
  • ·regulation of DNA-templated transcription initiation
  • ·transcription antitermination

Immune signalling

  • ·bacterial-type flagellum-dependent cell motility

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Drugs targeting this protein

1

Whether each drug engages this protein directly or through a complex, and how many other targets are recorded for it. Direct binders with few recorded targets are listed first.

Rifampin
Inhibitor

Bacterial DNA-directed RNA polymerase inhibitor

Acts on a complex — shared with rpoB, rpoA, rpoC · 1 of 4 recorded protein targets

ChEMBL mechanism, action type and target identity. Open Targets clinical status and indications.

Clinical trials

30

Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein.

An Open-Label, Single-Dose Study to Assess the Effect of Food Intake and Drug-Drug Interactions of E7090 When Co-administered With Rabeprazole (Gastric Acid-Reducing Agent), or Rifampin (Strong CYP3A Inducer) in Healthy SubjectsPHASE1

COMPLETED · via Rifampin · NCT04565574

A 2-Part, Non-randomized, Open-label Study to Evaluate the Effect of Itraconazole, Rifampicin, Rabeprazole, and Omeprazole on the Pharmacokinetics of Belumosudil (KD025)PHASE1

COMPLETED · via Rifampin · NCT03530995

An Open-label Fixed Sequence Trial to Investigate the Potential Drug-drug Interaction When BI 907828 is Co-administered With an OATP1B1 and/or OATP1B3 Transporter Inhibitor or With a CYP3A4 Inhibitor in Patients With Various Solid TumoursPHASE1

COMPLETED · via Rifampin · NCT05372367

A Seamless Phase 2B/C Platform Trial to Evaluate Multiple Regimens and Durations of Treatment in Pulmonary TuberculosisPHASE2

RECRUITING · via Rifampin · NCT06114628

A Two-part, Phase I, Open-label, Multicenter, Two-period, One-sequence Study to Investigate the Effect of Itraconazole and Rifampin on the PK of Vemurafenib at Steady StatePHASE1

COMPLETED · via Rifampin · NCT02608034

Effect of P-gp Inhibition, OATP-inhibition and Food on the Kinetics of a Single Oral Dose BI 685509 in Healthy Male SubjectsPHASE1

COMPLETED · via Rifampin · NCT03116893

Show remaining trials (24)
Safety of Rifampicin at High Dose for the Treatment of Adult Subjects With Complex Drug Susceptible Pulmonary and Extrapulmonary TuberculosisPHASE2

UNKNOWN · via Rifampin · NCT04768231

The Effect of High Dose Rifampicin on the Activity of Cytochrome P450 Enzymes and P-glycoprotein in Patients With Pulmonary Tuberculosis: a Cocktail Phenotyping StudyPHASE1

COMPLETED · via Rifampin · NCT04525235

The Study of Standardized Preoperative Anti-tuberculosis Treatment of Surgical Treatment of Spinal Tuberculosis PatientsPHASE4

UNKNOWN · via Rifampin · NCT02477852

A Randomized, Phase 2b Study of a Double-Dose Lopinavir/Ritonavir-Based Antiretroviral Regimen With Rifampin-Based Tuberculosis Treatment Versus a Standard-Dose Lopinavir/Ritonavir-Based Antiretroviral Regimen With Rifabutin-Based Tuberculosis Treatment With or Without Raltegravir in HIV-1-Infected Persons Requiring Treatment for Active TB and HIVPHASE2

TERMINATED · via Rifampin · NCT01601626

Testing New Strategies for Patients Hospitalised With HIV-associated Disseminated TuberculosisPHASE3

ACTIVE_NOT_RECRUITING · via Rifampin · NCT04951986

A Phase 1 Study of Oral TAK-788 to Evaluate the Drug-Drug Interaction With Itraconazole and Rifampin in Healthy Adult SubjectsPHASE1

COMPLETED · via Rifampin · NCT03928327

An Open-Label Phase I Study to Assess the Effect of Rifampicin on the Pharmacokinetics of Eribulin Mesylate (E7389) in Subjects With Advanced Solid TumorsPHASE1

COMPLETED · via Rifampin · NCT03002493

An Open-Label, Phase 1 Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Potential of CCX168 With Concomitant MedicationsPHASE1

COMPLETED · via Rifampin · NCT06004947

A Drug-drug Interaction Study to Evaluate the Effect of Rifampicin and Cyclosporine on the Pharmacokinetics of Methotrexate in Healthy SubjectsPHASE1

ACTIVE_NOT_RECRUITING · via Rifampin · NCT07196449

Evaluating Pharmacokinetics and Whole Blood Bactericidal Activity Against Mycobacterium Tuberculosis of Single 'High' Doses of Rifampicin in Healthy VolunteersPHASE1

SUSPENDED · via Rifampin · NCT02387242

Impact of LTBI Treatment on Glucose Tolerance and Chronic InflammationPHASE4

COMPLETED · via Rifampin · NCT04830462

A Phase I, Open-Label, Non-Randomised, Multicentre Study to Assess the Effect of Rifampicin (a CYP3A4 Inducer) on the Pharmacokinetics of AZD9291 in Patients With EGFRm Positive NSCLC Whose Disease Has Progressed on an EGFR TKIPHASE1

COMPLETED · via Rifampin · NCT02197247

Rifapentine- And Moxifloxacin-Containing Short-Course Regimens for Mild Spinal Tuberculosis: A Multicenter, Randomized, Non-inferiority Clinical TrialPHASE2

NOT_YET_RECRUITING · via Rifampin · NCT06917495

An Open-label, Fixed-sequence, Phase 1 Clinical Trial to Evaluate the Effect of Clarithromycin/Rifampicin on the Pharmacokinetics of DA-8010 in Healthy AdultsPHASE1

COMPLETED · via Rifampin · NCT05991401

Phase I, Open-label, 3-way Crossover Trial in Healthy Volunteers to Determine the Drug-drug Interaction Between TMC435350 and Rifampin After Multiple Dosing.PHASE1

COMPLETED · via Rifampin · NCT00741169

A Non-randomised, Open-label, Sequential, Multicentre, Two-part, Phase I Study to Assess the Effect of Rifampicin, a CYP Inducer, on the Pharmacokinetics of Olaparib Following Oral Dosing of a Tablet Formulation in Patients With Advanced Solid TumoursPHASE1

COMPLETED · via Rifampin · NCT01929603

A Single-center, Non-randomized, Open-lable, Self-controlled Clinical Trial to Evaluate JAB-21822 Drug-drug Interactions in Healthy SubjectsPHASE1

COMPLETED · via Rifampin · NCT06162169

Shortened Regimens for First Diagnosed Smear Positive Drug Susceptible Pulmonary Tuberculosis: a Randomised Controlled Non-inferiority TrialPHASE4

UNKNOWN · via Rifampin · NCT02901288

The Treatment of Pulmonary Mycobacterium Tuberculosis in HIV InfectionPHASE3

COMPLETED · via Rifampin · NCT00001033

Rifabutin Versus Rifampicin for Treatment of Staphylococcal Prosthetic Joint Infection Treated With Debridement, Antibiotics and Implant Retention (DAIR Strategy): a Multicenter Randomized, Open-label, Non-inferiority TrialPHASE3

RECRUITING · via Rifampin · NCT04672525

Mechanical Bowel Preparation With or Without Oral Antibiotics in Left Sided Colorectal Cancer Surgery: A Randomized Trial (MEBOA Trial)NA

ENROLLING_BY_INVITATION · via Rifampin · NCT07429760

Evaluation of Drug-Drug Interactions Between CS0159 Tablets and Rifampicin/Itraconazole and the Effect of a High-Fat Meal on the Pharmacokinetic Characteristics of CS0159 Tablets in Healthy Adult ParticipantsPHASE1

COMPLETED · via Rifampin · NCT07429331

Rosuvastatin Evaluation as a Tuberculosis Treatment AdjunctPHASE2

UNKNOWN · via Rifampin · NCT04504851

Relative Bioavailability of Single Doses of 150 mg Dabigatran Etexilate (Capsule)When Administered Alone, After Seven Days of Dosing With 600 mg Rifampicin(Tablet), and Seven Days and Fourteen Days After Last Administration of Rifampicin in Healthy Male and Female Volunteers (an Open Label, Fixed Sequence, Phase I Study)PHASE1

COMPLETED · via Rifampin · NCT02173717

ClinicalTrials.gov via the drug-target graph.

What's happening now

4

Recent activity around this target, drawn from one canonical event stream. Every item is reached through a drug that targets this protein, so each event is news about that drug rather than about the protein directly.

  1. Regulatory approval2026-06-29

    Approval: RIFAMPIN (ANDA219918)

    fda · regulatory · fda · via Rifampin

  2. New publication2024-03-28
    Estimation of country-specific tuberculosis resistance antibiograms using pathogen genomics and machine learning.

    BMJ global health · 2024 · 4 citations · Europe PMC · via Rifampin

  3. New publication2006-03-30
    Potent twice-weekly rifapentine-containing regimens in murine tuberculosis.

    American journal of respiratory and critical care medicine · 2006 · 60 citations · Europe PMC · via Rifampin

  4. New publication2005-09-01
    Weekly moxifloxacin and rifapentine is more active than the denver regimen in murine tuberculosis.

    American journal of respiratory and critical care medicine · 2005 · 43 citations · Europe PMC · via Rifampin

Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.